argenx

An arrow incrementally going up stairs before pointing straight up Blue background

Biotech

Leo's eczema prospect hits primary endpoint in phase 2b

Leo shared phase 2b data on temtokibart, reporting that the top three doses of the IL-22RA1 blocker beat placebo on the primary endpoint.

Nick Paul Taylor May 9, 2025 7:30am

target reach ladder climb meet win beat competition

J&J's phase 2 Sjögren's data support FcRn strategy

Jun 17, 2024 8:47am

graphic image of a cube with an arrow nailing the bullseye

Roivant FcRn inhibitor avoids cholesterol problem, shares spike

Sep 26, 2023 10:56am

A business window with a sign that says welcome we are open

Metrodora opens neuroimmune research center in Salt Lake City

Apr 19, 2023 11:11am

business deal strategy partnership gears plan

Argenx, Genmab join forces to expand into new therapeutic areas

Apr 17, 2023 6:20am

UCB races to regulators after $2B rare disease bet delivers data

Feb 4, 2022 8:25am